SCHEMBL6417214

SCHEMBL6417214

Cc1n[nH]c(C)c1Sc1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ TDP1 Q9NUW8 1/20 0.60
▸ TSHR P16473 1/20 0.54
▸ LMNA P02545 2/20 0.49
▸ TYMS P04818 3/20 0.43
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ PTGS1 P23219 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ DHFR P00374 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ IDO1 P14902 1/20 0.37
▸ TDO2 P48775 1/20 0.37
▸ NOTUM Q6P988 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ DHODH Q02127 1/20 0.36
▸ DYRK1A Q13627 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416951 0.76 ALDH1A1 (1.00) KDM4EALDH1A1TDP1TSHRLMNA
SCHEMBL6417909 0.73 MAPT (0.49) KDM4EALDH1A1TDP1TSHRLMNA
SCHEMBL4239165 0.68 ENPP3 (0.59) KDM4EALDH1A1LMNASMN1; SMN2NPSR1
SCHEMBL6416329 0.67 TYMS (0.45) KDM4ELMNATYMSNPC1RAB9A
SCHEMBL576260 0.66 MEN1 (0.48) ALDH1A1TSHRLMNANPSR1DHFR
SCHEMBL7938033 0.65 ACHE (0.68) ALDH1A1TDP1TSHRNPSR1MAPT
SCHEMBL22242018 0.65 — —
SCHEMBL21609607 0.65 LMNA (0.51) KDM4ELMNATYMSNPC1RAB9A
SCHEMBL4230856 0.64 LMNA (0.62) KDM4EALDH1A1TSHRLMNASMN1; SMN2
SCHEMBL8045852 0.64 ITK (0.46) KEAP1ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050119489-A1 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor BAYER HEALTHCARE AG (DE) 2005-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119489-A1 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor HTR2C, HTR2A, HTR2B KDM4E 2840/4885ALDH1A1 813/4885TDP1 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback